Suppr超能文献

靶向恶性疟原虫的细胞应激反应以克服青蒿素耐药性。

Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance.

作者信息

Dogovski Con, Xie Stanley C, Burgio Gaetan, Bridgford Jess, Mok Sachel, McCaw James M, Chotivanich Kesinee, Kenny Shannon, Gnädig Nina, Straimer Judith, Bozdech Zbynek, Fidock David A, Simpson Julie A, Dondorp Arjen M, Foote Simon, Klonis Nectarios, Tilley Leann

机构信息

Department of Biochemistry and Molecular Biology and ARC Centre of Excellence for Coherent X-ray Science, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.

John Curtin School of Medical Research, the Australian National University, Canberra, Australian Capital Territory, Australia; Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales, Australia.

出版信息

PLoS Biol. 2015 Apr 22;13(4):e1002132. doi: 10.1371/journal.pbio.1002132. eCollection 2015 Apr.

Abstract

Successful control of falciparum malaria depends greatly on treatment with artemisinin combination therapies. Thus, reports that resistance to artemisinins (ARTs) has emerged, and that the prevalence of this resistance is increasing, are alarming. ART resistance has recently been linked to mutations in the K13 propeller protein. We undertook a detailed kinetic analysis of the drug responses of K13 wild-type and mutant isolates of Plasmodium falciparum sourced from a region in Cambodia (Pailin). We demonstrate that ART treatment induces growth retardation and an accumulation of ubiquitinated proteins, indicative of a cellular stress response that engages the ubiquitin/proteasome system. We show that resistant parasites exhibit lower levels of ubiquitinated proteins and delayed onset of cell death, indicating an enhanced cell stress response. We found that the stress response can be targeted by inhibiting the proteasome. Accordingly, clinically used proteasome inhibitors strongly synergize ART activity against both sensitive and resistant parasites, including isogenic lines expressing mutant or wild-type K13. Synergy is also observed against Plasmodium berghei in vivo. We developed a detailed model of parasite responses that enables us to infer, for the first time, in vivo parasite clearance profiles from in vitro assessments of ART sensitivity. We provide evidence that the clinical marker of resistance (delayed parasite clearance) is an indirect measure of drug efficacy because of the persistence of unviable parasites with unchanged morphology in the circulation, and we suggest alternative approaches for the direct measurement of viability. Our model predicts that extending current three-day ART treatment courses to four days, or splitting the doses, will efficiently clear resistant parasite infections. This work provides a rationale for improving the detection of ART resistance in the field and for treatment strategies that can be employed in areas with ART resistance.

摘要

恶性疟原虫的成功控制在很大程度上依赖于青蒿素联合疗法的治疗。因此,有报道称对青蒿素(ARTs)的耐药性已经出现,且这种耐药性的流行率正在上升,这令人担忧。最近,ART耐药性与K13螺旋桨蛋白的突变有关。我们对来自柬埔寨拜林地区的恶性疟原虫K13野生型和突变型分离株的药物反应进行了详细的动力学分析。我们证明,ART治疗会导致生长迟缓以及泛素化蛋白的积累,这表明细胞应激反应激活了泛素/蛋白酶体系统。我们发现,耐药寄生虫表现出较低水平的泛素化蛋白以及细胞死亡延迟,这表明细胞应激反应增强。我们发现,通过抑制蛋白酶体可以靶向应激反应。因此,临床使用的蛋白酶体抑制剂能强烈增强ART对敏感和耐药寄生虫的活性,包括表达突变型或野生型K13的同基因系。在体内对伯氏疟原虫也观察到了协同作用。我们建立了一个详细的寄生虫反应模型,首次使我们能够根据体外ART敏感性评估推断体内寄生虫清除情况。我们提供的证据表明,耐药性的临床标志物(寄生虫清除延迟)是药物疗效的间接指标,因为循环中形态未改变的无活力寄生虫持续存在,并且我们提出了直接测量活力的替代方法。我们的模型预测,将目前为期三天的ART治疗疗程延长至四天或分剂量给药,将有效清除耐药寄生虫感染。这项工作为改进现场ART耐药性检测以及在存在ART耐药性的地区可采用的治疗策略提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf54/4406523/748b218c75a8/pbio.1002132.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验